Tyrosine kinase inhibitors against VEGFR, including cediranib, sorafenib, sunitinib, and vandetanib, have been tested in Phase I/II trials and their efficacy is now being tested for GBM [228]. This evidence concerns the gene KDR and glioblastoma.